Asia Pacific active pharmaceutical ingredients (API) market will grow by 8.1% annually with a total addressable market cap of $ 1,098.6 billion over 2023-2032, driven by rising adoption of biologics in disease management, increasing regulatory approvals, patent expiration of major drugs, growing trend of outsourcing and increase in geriatric population.
Highlighted with 88 tables and 75 figures, this 196-page report "Asia Pacific Active Pharmaceutical Ingredients (API) Market 2022-2032 by Molecule (Small, Large), Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity" is based on a comprehensive research of the entire Asia Pacific active pharmaceutical ingredients (API) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific active pharmaceutical ingredients (API) market in every aspect of the classification from perspectives of Molecule, Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.
Based on Molecule, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Small Molecule APIs
• Large Molecule APIs
Based on Synthesis, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Synthetic API
o Branded Synthetic API
o Generic Synthetic API
• Biotech API
o by type
Monoclonal Antibodies
Recombinant Proteins
Vaccines
Other Biotech APIs
o by Category
Innovative Biologic API
Generic Biosimilar API
o by Expression
Mammalian Expression
Microbial Expression
Yeast Expression
Insect Expression
Other Expression Technologies
• HPAPI
o Branded HPAPI
o Generic HPAPI
Based on Manufacturing Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Captive Manufacturing
o Branded Captive API
o Generic Captive API
• Merchant Manufacturing
o by Drug Type
Branded Merchant API
Generic Merchant API
o by Drug Synthesis
Merchant Synthetic API
Merchant Biotech API
By Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications
By Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Catalent Inc.
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 32
2.2 Major Growth Drivers 36
2.3 Market Restraints and Challenges 44
2.4 Emerging Opportunities and Market Trends 47
2.5 Porter's Fiver Forces Analysis 51
3 Segmentation of Asia Pacific Market by Molecule 55
3.1 Market Overview by Molecule 55
3.2 Small Molecule APIs 57
3.3 Large Molecule APIs 58
4 Segmentation of Asia Pacific Market by Synthesis 59
4.1 Market Overview by Synthesis 59
4.2 Synthetic API 61
4.2.1 Branded Synthetic API 62
4.2.2 Generic Synthetic API 63
4.3 Biotech API 64
4.3.1 Biotech API by Drug Type 65
4.3.1.1 Monoclonal Antibodies 66
4.3.1.2 Recombinant Proteins 67
4.3.1.3 Vaccines 68
4.3.1.4 Other Biotech APIs 69
4.3.2 Biotech API by Category 70
4.3.2.1 Innovative Biologic API 71
4.3.2.2 Generic Biosimilar API 72
4.3.3 Biotech API by Expression Technology 73
4.3.3.1 Mammalian Expression 74
4.3.3.2 Microbial Expression 75
4.3.3.3 Yeast Expression 76
4.3.3.4 Insect Expression 77
4.3.3.5 Other Expression Technologies 78
4.4 HPAPI 79
4.4.1 Branded HPAPI 80
4.4.2 Generic HPAPI 81
5 Segmentation of Asia Pacific Market by Manufacturing Process 82
5.1 Market Overview by Manufacturing Process 82
5.2 Captive Manufacturing 84
5.2.1 Branded Captive API 85
5.2.2 Generic Captive API 86
5.3 Merchant Manufacturing 87
5.3.1 Merchant Manufacturing by Drug Type 88
5.3.1.1 Branded Merchant API 89
5.3.1.2 Generic Merchant API 90
5.3.2 Merchant Manufacturing by Drug Synthesis 91
5.3.2.1 Merchant Synthetic API 92
5.3.2.2 Merchant Biotech API 93
6 Segmentation of Asia Pacific Market by Therapeutic Application 94
6.1 Market Overview by Therapeutic Application 94
6.2 Infectious Diseases 96
6.3 Oncology 97
6.4 Ophthalmology 98
6.5 Cardiovascular Disorders 99
6.6 Central Nervous System 100
6.7 Pulmonary Disorders 101
6.8 Orthopedics 102
6.9 Other Applications 103
7 Segmentation of Asia Pacific Market by Drug Type 104
7.1 Market Overview by Drug Type 104
7.2 Branded Prescription Drugs 106
7.3 Generic Prescription Drugs 107
7.4 OTC Drugs 108
8 Asia-Pacific Market 2022-2032 by Country 109
8.1 Overview of Asia-Pacific Market 109
8.2 China 112
8.3 Japan 114
8.4 India 117
8.5 Australia 119
8.6 South Korea 121
8.7 Rest of APAC Region 123
9 Competitive Landscape 125
9.1 Overview of Key Vendors 125
9.2 New Product Launch, Partnership, Investment, and M&A 128
9.3 Company Profiles 129
AbbVie Inc. 129
Astrazeneca 131
Aurobindo Pharma Ltd. 136
BASF 139
Bayer AG 142
Boehringer Ingelheim 146
Catalent Inc. 151
Dr. Reddy's Laboratories 154
F. Hoffmann-La Roche 156
GlaxoSmithKline plc 159
Lonza Group 164
Lupin Limited 168
Merck & Co., Inc. 171
Mylan NV 174
Novartis International AG 177
Pfizer Inc. 180
Sanofi 185
Sun Pharmaceutical Industries Ltd. 188
Teva Pharmaceutical Industries Ltd. 191
Thermo Fisher Scientific 193
Related Reports and Products 196
The Freeze-drying Pharmaceutical Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufa...
The Active RFID Asset Management Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufa...
Market Overview
The Asia Pacific Vanadium Market is poised for substantial growth from 2024 to 2034, driven by increasing demand across various industries and technological advancements in vanadium production. The market is projected to reach USD XX.XX billion by 2034, growing at a comp...
Market Overview
The Asia Pacific Vascular Closure Devices Market is anticipated to experience substantial growth from 2024 to 2034. The market's expansion is fueled by advancements in vascular closure technologies, increasing prevalence of cardiovascular diseases, and the growing adopti...
Market Overview
The Europe Vascular Closure Devices Market is poised for significant growth from 2024 to 2034, driven by advancements in minimally invasive procedures, increasing procedural volumes, and a growing preference for vascular closure solutions that enhance patient outcomes. T...
Market Overview
The North America Vascular Closure Devices (VCD) Market is anticipated to witness significant growth from 2024 to 2034, driven by the increasing volume of minimally invasive cardiovascular procedures, rising prevalence of cardiovascular diseases, and advancements in vasc...
Market Overview
The Global Vascular Closure Devices Market is projected to grow substantially from 2024 to 2034, driven by the increasing volume of minimally invasive cardiovascular procedures and the rising demand for fast, efficient vascular closure solutions. In 2024, the market is v...
Market Overview
The Asia Pacific Nuclear Medicine Market is poised for significant growth from 2024 to 2034, driven by advancements in nuclear imaging technologies, increased application in various medical fields, and rising healthcare investments across the region. The market is expect...
Market Overview
The Asia Pacific Anti-Pollution Mask Market is set to experience substantial growth from 2024 to 2034. Starting with a market valuation of USD XX.XX billion in 2024, it is projected to reach USD XX.XX billion by 2034, reflecting a significant compound annual growth rate ...
Market Overview
The Asia Pacific Ethnic Wear Market is anticipated to experience robust growth from 2024 to 2034. Starting with a market valuation of USD XX.XX billion in 2024, it is projected to surge to USD XX.XX billion by 2034, reflecting a strong compound annual growth rate (CAGR) ...